A detailed history of Barclays PLC transactions in Chimerix Inc stock. As of the latest transaction made, Barclays PLC holds 2,500 shares of CMRX stock, worth $2,425. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,500
Previous 327,356 99.24%
Holding current value
$2,425
Previous $347,000 99.42%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.87 - $1.05 $282,624 - $341,098
-324,856 Reduced 99.24%
2,500 $2,000
Q1 2024

May 15, 2024

SELL
$0.91 - $1.26 $513,562 - $711,086
-564,354 Reduced 63.29%
327,356 $347,000
Q4 2023

Feb 15, 2024

BUY
$0.9 - $1.06 $51,449 - $60,595
57,166 Added 6.85%
891,710 $858,000
Q2 2023

Aug 03, 2023

SELL
$1.1 - $1.54 $46,957 - $65,741
-42,689 Reduced 4.87%
834,544 $1.01 Million
Q1 2023

May 04, 2023

BUY
$1.19 - $2.09 $237,108 - $416,434
199,251 Added 29.39%
877,233 $1.11 Million
Q4 2022

Feb 13, 2023

BUY
$1.67 - $2.35 $419,383 - $590,150
251,128 Added 58.83%
677,982 $1.26 Million
Q3 2022

Nov 03, 2022

BUY
$1.81 - $2.76 $757,483 - $1.16 Million
418,499 Added 5008.96%
426,854 $825,000
Q2 2022

Aug 12, 2022

SELL
$1.34 - $5.34 $5,142 - $20,494
-3,838 Reduced 31.48%
8,355 $17,000
Q1 2022

May 16, 2022

SELL
$4.58 - $6.8 $349,971 - $519,608
-76,413 Reduced 86.24%
12,193 $56,000
Q4 2021

Feb 14, 2022

BUY
$5.23 - $7.18 $305,039 - $418,773
58,325 Added 192.61%
88,606 $570,000
Q3 2021

Nov 09, 2021

BUY
$5.94 - $8.75 $121,912 - $179,585
20,524 Added 210.35%
30,281 $188,000
Q2 2021

Aug 13, 2021

SELL
$7.54 - $9.79 $302,866 - $393,244
-40,168 Reduced 80.46%
9,757 $79,000
Q1 2021

May 13, 2021

BUY
$4.76 - $11.25 $162,435 - $383,906
34,125 Added 215.98%
49,925 $480,000
Q4 2020

Feb 11, 2021

SELL
$2.43 - $5.42 $15,464 - $34,492
-6,364 Reduced 28.71%
15,800 $77,000
Q3 2020

Nov 12, 2020

SELL
$2.3 - $3.72 $24,225 - $39,182
-10,533 Reduced 32.21%
22,164 $55,000
Q2 2020

Aug 12, 2020

BUY
$1.33 - $3.63 $22,270 - $60,784
16,745 Added 104.97%
32,697 $101,000
Q1 2020

May 13, 2020

SELL
$1.27 - $2.33 $41,803 - $76,694
-32,916 Reduced 67.36%
15,952 $23,000
Q4 2019

Feb 10, 2020

BUY
$1.3 - $2.72 $31,816 - $66,569
24,474 Added 100.33%
48,868 $99,000
Q3 2019

Nov 14, 2019

SELL
$1.93 - $4.21 $14,525 - $31,684
-7,526 Reduced 23.58%
24,394 $58,000
Q2 2019

Aug 14, 2019

BUY
$2.05 - $4.32 $36,004 - $75,872
17,563 Added 122.33%
31,920 $138,000
Q1 2019

May 15, 2019

BUY
$1.79 - $3.12 $23,073 - $40,216
12,890 Added 878.66%
14,357 $30,000
Q4 2018

Feb 14, 2019

SELL
$2.24 - $3.9 $61,906 - $107,784
-27,637 Reduced 94.96%
1,467 $3,000
Q3 2018

Nov 14, 2018

BUY
$3.58 - $4.9 $90,430 - $123,774
25,260 Added 657.13%
29,104 $112,000
Q2 2018

Aug 14, 2018

SELL
$4.43 - $5.14 $29,472 - $34,196
-6,653 Reduced 63.38%
3,844 $18,000
Q1 2018

May 15, 2018

BUY
$4.65 - $5.9 $14,442 - $18,325
3,106 Added 42.02%
10,497 $55,000
Q4 2017

Feb 14, 2018

SELL
$4.32 - $5.52 $234,100 - $299,128
-54,190 Reduced 88.0%
7,391 $34,000
Q3 2017

Nov 14, 2017

BUY
$4.35 - $5.25 $267,877 - $323,300
61,581
61,581 $324,000

Others Institutions Holding CMRX

About CHIMERIX INC


  • Ticker CMRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,622,896
  • Market Cap $85M
  • Description
  • Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...
More about CMRX
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.